Login Register Cart 0
Generic placeholder image

Recent Patents on Anti-Cancer Drug Discovery

Editor-in-Chief

ISSN (Print): 1574-8928
ISSN (Online): 2212-3970

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Metallodrugs as Anticancer Chemotherapeutics and Diagnostic Agents: A Critical Patent Review (2010-2020)

Author(s): Eirini Fotopoulou, Ioannis Titilas and Luca Ronconi*

Volume 17, Issue 1, 2022

Published on: 26 November, 2021

Page: [42 - 54] Pages: 13

DOI: 10.2174/1574892816666210907101146

Price: $65

conference banner
Abstract

Background: The development of metallodrugs with potential applications in cancer treatment and diagnosis has been a hot topic since the approval and subsequent marketing of the anticancer drug cisplatin in 1978. Since then, thousands of metal-based derivatives have been reported and evaluated for their chemotherapeutic or tumor imaging properties, but only a very limited number gained clinical status. Nonetheless, research in the field has been increasing exponentially over the years, especially in a view to exploiting novel drug designing approaches and strategies aimed at improving pharmacological outcomes and, at the same time, reducing side-effects.

Objectives: This review article reports on the patents filed during the last decade and strictly focusing on the development of metal-based anticancer and diagnostic agents. The goal is to identify the latest trends and designing strategies in the field, which would represent a valuable starting point to researchers interested in the development of metallodrugs.

Methods: The most relevant patents filed in the 2010-2020 timeframe have been retrieved from various databases using dedicated search engines (such as SciFinder, Google Patents, PatentPak, Espacenet, Global Dossier, PatentScope), sorted by type of metallodrug and screened to include those reporting a substantial amount of biological data.

Results: The majority of patents here reviewed are concerned with metallodrugs (mostly platinum- based) showing interesting pharmacological properties but no specific tumor-targeting features. Nonetheless, some promising trends in the development of novel drug delivery strategies and/or metallodrugs with potential applications in targeted chemotherapy are envisaged.

Conclusion: In this review, the latest trends in the development of metallodrugs from recent patents are summarized and critically discussed. Such trends would be of interest not only to the scientific community but also to lay audiences aiming to broaden their knowledge of the field and industrial stakeholders potentially interested in the exploitation and commercialization of this class of pharmaceuticals.

Keywords: Metallodrugs, metal-based chemotherapeutics, anticancer, tumor imaging, chemotherapy, cancer diagnosis, targeted chemotherapy.

« Previous Next »
[1]
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68(6): 394-424.
[http://dx.doi.org/10.3322/caac.21492] [PMID: 30207593]
[2]
McCormick PJ. Cancer tsunami: Emerging trends, economic burden, and perioperative implications. Curr Anesthesiol Rep 2018; 8(4): 348-54.
[http://dx.doi.org/10.1007/s40140-018-0294-1] [PMID: 31130826]
[3]
Miller KD, Nogueira L, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin 2019; 69(5): 363-85.
[http://dx.doi.org/10.3322/caac.21565] [PMID: 31184787]
[4]
Komeda S, Casini A. Next-generation anticancer metallodrugs. Curr Top Med Chem 2012; 12(3): 219-35.
[http://dx.doi.org/10.2174/156802612799078964] [PMID: 22236158]
[5]
Ghosh S. Cisplatin: The first metal based anticancer drug. Bioorg Chem 2019; 88: 102925.
[http://dx.doi.org/10.1016/j.bioorg.2019.102925] [PMID: 31003078]
[6]
Aldossary SA. Review on pharmacology of Cisplatin: Clinical use, toxicity and mechanism of resistance of cisplatin. Biomed Pharmacol J 2019; 12(1): 7-15.
[http://dx.doi.org/10.13005/bpj/1608]
[7]
Guo Z, Sadler PJ. Medicinal inorganic chemistry. Adv Inorg Chem 1999; 49: 183-306.
[8]
Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 2007; 7(8): 573-84.
[http://dx.doi.org/10.1038/nrc2167] [PMID: 17625587]
[9]
Johnstone TC, Suntharalingam K, Lippard SJ. The next generation of platinum drugs: Targeted Pt(II) agents, nanoparticle delivery, and Pt(IV) prodrugs. Chem Rev 2016; 116(5): 3436-86.
[http://dx.doi.org/10.1021/acs.chemrev.5b00597] [PMID: 26865551]
[10]
Hanif M, Hartinger CG. Anticancer metallodrugs: Where is the next cisplatin? Future Med Chem 2018; 10(6): 615-7.
[http://dx.doi.org/10.4155/fmc-2017-0317] [PMID: 29411994]
[11]
Murray BS, Dyson PJ. Recent progress in the development of organometallics for the treatment of cancer. Curr Opin Chem Biol 2020; 56: 28-34.
[http://dx.doi.org/10.1016/j.cbpa.2019.11.001] [PMID: 31812831]
[12]
Contel M. Unconventional anticancer metallodrugs and strategies to improve their pharmacological profile. Inorganics (Basel) 2019; 7(7): 88.
[http://dx.doi.org/10.3390/inorganics7070088]
[13]
Wheate NJ, Walker S, Craig GE, Oun R. The status of platinum anticancer drugs in the clinic and in clinical trials. Dalton Trans 2010; 39(35): 8113-27.
[http://dx.doi.org/10.1039/c0dt00292e] [PMID: 20593091]
[14]
Anthony EJ, Bolitho EM, Bridgewater HE, et al. Metallodrugs are unique: Opportunities and challenges of discovery and development. Chem Sci (Camb) 2020; 11(48): 12888-917.
[http://dx.doi.org/10.1039/D0SC04082G] [PMID: 34123239]
[15]
SciFinder - chemical abstracts service. Available from: https://scifinder.cas.org [Last accessed on February 26th, 2021]
[16]
Che CM. Metal complexes of thiourea and derivatives as metal delivering anti-cancer and anti-inflammatory agents. US8722897, 2014.
[17]
Akerman KJ, Akerman P, Munro OQ. Gold complexes for use in the treatment of cancer. WO2011158176, 2012.
[18]
Mandal SS, Ansari KI, Grant JD III. Apoptotic and anti-tumor activities of metallo-salens. US8198322, 2012.
[19]
Che CM, Sun WR, Chow L, Yan J. Pharmaceutical composition containing cyclometalated n-heterocyclic carbene complexes for cancer treatment. CN102741262, 2014.
[20]
Che CM, Zou T. Novel gold(III) complexes containing N-heterocyclic carbene ligand, synthesis, and their applications in cancer treatment and thiol detection. WO2014075394, 2014.
[21]
Szczepaniak S, Szczepaniak E, Szczepaniak R, Szczepaniak D, Szczepaniak M. Water-soluble gold (III) complexes, methods of producing water-soluble gold (III) complexes and their use. WO2019008013, 2019.
[22]
Al-Jaroudi S, Altaf M, Al-Saadi A, Isab AA. Mixed ligand gold (III) complexes and methods thereof. US9487542, 2016.
[23]
Munro OQ, Akerman KJ, Akerman P. Gold complexes for use in the treatment of cancer. US9346832, 2016.
[24]
Contel M, Fernandez-Gallardo J, Elie BT, Ramos JW. Titanocene-gold derivatives comprising thiolato ligands. US9315531, 2016.
[25]
Al-Jaroudi S, Altaf M, Al-Saadi A, Isab AA. Mixed ligand gold (III) complexes as anti-cancer agents. US9481693, 2016.
[26]
Al-Jaroudi S, Altaf M, Al-Saadi A, Isab AA. Method for treating prostate cancer and/or gastrointestinal cancer. US9649292, 2017.
[27]
Al-Jaroudi SS, Alhoshani A, Altaf M, Isab AA. Mixed ligand gold (I) complexes as anti-cancer agents. US10077280, 2018.
[28]
Al-Jaroudi SS, Alhoshani A, Altaf M, Isab AA. Cancer cell-containing composition. US10273257, 2019.
[29]
Al-Jaroudi SS, Alhoshani A, Altaf M, Isab AA. Gold complex- containing cancer activity composition. US10301335, 2019.
[30]
Ishikawa Y, Eguchi H. Metal salen complex compound, local anesthetic, and anti-malignant tumor agent. EP2738158, 2019.
[31]
Ishikawa Y, Eguchi H. Anti-cancer agent and method for killing cancer cells. WO2016046989, 2016.
[32]
Nagai M, Shen J. Transition metal complexes of bis[thiohydrazide amide] compounds. US9174935, 2015.
[33]
Cowan JA, Cowan AS, Palmer DT. Metallodrugs having improved pharmacological properties, and methods of manufacture and use thereof. US8859492, 2014.
[34]
Marzano C, Porchia M, Tisato F, et al. [CU(thp)4]n[X]-n compounds for the treatment of a broad range of human solid tumors, including refractory tumors. US9114149, 2015.
[35]
Jaouen G, Vessieres-Jaouen A, Plazuk D. Ferrocene derivatives with anticancer activity. US8426462, 2013.
[36]
Anselmo Viegas Garcia MH, Ferreira Morais TS, Antunes Tomaz Diniz AI, Marujo Marques F, Fernandes Mendes F. Transition metal complexes for pharmaceutical applications. WO2013038395, 2013.
[37]
Demirci TB, Ulküseven B, Kuruca DS. New thiosemicarbazone chelates having anticancer activity. EP2881399, 2018.
[38]
Sheshbaradaran H. Method to prevent cancer metastasis to bone. US9725471, 2017.
[39]
Hlavinka ML, Yang Q, Murph MM. Use of metallocene compounds for cancer treatment. US9441000, 2016.
[40]
Piccariello T. Metal coordinated compositions. US7799937, 2010.
[41]
Piccariello T. Metal coordinated compositions. US8389726, 2013.
[42]
Piccariello T, Price JD, Oberlender RA, Mulhare ME, Spencer MC, Palmer SB. Coordination complexes, pharmaceutical solutions comprising coordination complexes, and methods of treating patients. US8779175, 2014.
[43]
Odani A. Metal complexes and anticancer agents comprising same as active ingredient. WO2011125911, 2011.
[44]
Içsel C, Ulukaya E, Yilmaz VT, Dimas K. Palladium complex with high anticancer activity. US9839643B2, 2017.
[45]
Liu Y, Wang Y. Application of water soluble platinum complex to preparation of tumor prevention and treatment medicines. CN102716146, 2014.
[46]
Liu Y, Wang Y. Application of fluorine-containing water-soluble platinum complex to preparation of tumor prevention and treatment medicines. CN102716144, 2014.
[47]
Braley C. Methods of treating platinum-resistant recurrent ovarian cancer with 4-iodo-3-nitrobenzamide in combination with an anti-metabolite and a platinum compound. WO2011153383, 2011.
[48]
Chang Q, Hou S, Li X, et al. Platinum(II) anti-cancer compound with selectivity for cancer cells. CN101967163, 2012.
[49]
Bierbach U, Ding S. Targeted delivery and prodrug designs for platinum-acridine anti-cancer compounds and methods thereof. WO2013033430, 2013.
[50]
Jiaju S, Yiguan Z. Dynamic anti-cancer platinum compound with two different ligands at syn-position. CN103374042, 2013.
[51]
Shaohua G, Gang X. Antitumor platinum(II) complex and use thereof in preparation of antitumor medicine. CN102127120, 2013.
[52]
Cheng Q, Liu Y, Min Y, Shi H. Anti-cancer medicinal aspirin platinum complex and preparation method thereof. CN102942594, 2013.
[53]
Chen X, Hou S, Liu W, et al. Dichloroacetoxyl-containing platinum(II) anticancer coordination compound. CN101914117, 2013.
[54]
Huang H, Ji L, Mao Z, Tan C, Zheng X. Organic hydridized tetra- core platinum complex and preparation method thereof as well as application in antitumor medicament preparation. CN102250150, 2013.
[55]
Yong Hei. Combination of motesanib, a taxane and a platinum- containing anti-cancer drug for use in the treatment of non-small cell lung cancer in a population subset. KR20140022876, 2014.
[56]
Shi S, Wang X, Yao T. Novel latent antitumor drug platinum complex and preparation method thereof. CN103724376, 2014.
[57]
Peng J, Pu S, Wang Q. Novel synthetic method of antitumor drug heptyl platinum. CN104211734, 2014.
[58]
Hoeschele JD, Margiotta N, Gandin V, Petruzzella E, Marzano C. Method of treating colorectal cancer. US9220705, 2015.
[59]
Giacomini KM, More S. Platinum anticancer agents. US9217007, 2015.
[60]
Hou S, Jiang J, Liu W, et al. Platinum(II) antitumor compounds taking 3-oxo-cyclobutane-1,1-dicarboxylate as ligand. CN104086597, 2015.
[61]
Gou S, Zhao J. Antitumor platinum(II) complex by taking alkyl carboxylate radical as ligand. CN103224533, 2015.
[62]
Lu L, Yuan C, Zhu M. Binuclear platinum(II) complex as well as preparation method and application thereof. CN103467397, 2015.
[63]
Gou S. Anti-tumor bivalent platinum complex and preparation method for complex and ligand of complex. US9227991, 2016.
[64]
Davey CA, Ang WH, Chin CF. Platinum complexes as anticancer agents. WO2016028225, 2016.
[65]
Yu Y. A kind of Pt(IV with mixing axial part) kind anti-cancer drugs thing and preparation method. CN103860539, 2016.
[66]
Miodragovic DU, O'Halloran TV. Arsenoplatin anti-cancer agents. US9499574, 2016.
[67]
Bierbach U, Ding S. Cleavable conjugates of functionalized platinum-acridine and platinum-benzacridine agents and methods thereof. US9765103, 2017.
[68]
Lu L, Wu Y, Yuan C, Zhu M. A kind of Schiff bases platinum complex and its preparation method and application. CN104910212, 2017.
[69]
Isab AHAK, Altaf M. Bis-(triethylphosphine)platinum(II) complexes with thiones as anti-cancer agents. US9561237, 2017.
[70]
Giacomini KM, More S, Yee SW, Geier E, Wilson J. Platinum anticancer agents. WO2017091616, 2017.
[71]
Chen X, Yan Y, Meng X, Zhao F, Gao Z, Wen S. Platinum compounds of malonic acid derivative having leaving group containing amino or alkylamino. US9725477, 2017.
[72]
Zhu G, Ma L. Heterodinuclear platinum-ruthenium complexes, preparation thereof and therapeutic use thereof. US9650402, 2017.
[73]
Che CM, Hu D, Chan LF. Platinum complexes and methods of use thereof. WO2018024172, 2018.
[74]
Gamble AJ, Lynam JM, Walton PH. Synthesis and anticancer activity of ruthenium (11) cis-cis-1,3,5- triaminocyclohexane complexes. WO2013038134, 2013.
[75]
Reddy VD. Organometallic anti-cancer complexes. US8748484, 2014.
[76]
Garnett M. Ruthenium-sphingomyelin complexes and methods for their use in the treatment of tumors. WO2017200792, 2017.
[77]
Gao L, Jiang J, Li L, et al. Two (α-furnancarboxylic acid) vanadyl is as the novelty teabag of cancer therapy drug. CN103599107, 2015.
[78]
Meijboom R, Cronje MJ. Use of silver(I) complexes as anticancer agents. US9676801, 2017.
[79]
Yen MA, Gray HB, Grubbs RH, Palmer J. Derivatized corroles and metallocorroles and their use as imaging and therapeutic agents. US10035806, 2018.
[80]
Lascola CD. Manganese complexes with substituted bisphosphonates useful as imaging and therapeutic agents. WO2017184200, 2017.
[81]
Du Preez JGH, Wentzel M, Knoetze D. Aromatic compounds and metal complexes thereof. WO2012153253, 2013.
[82]
Biswas G, Dutta P, Mandal SK, et al. Fluorescent anticancer platinum drugs. WO2017064657, 2017.
[83]
Frank SJ, Martirosyan K. Cobalt-based MRI contrast agent and imaging system. US9555135, 2017.
[84]
Yang JJ, Liu Z, Li S, et al. Contrast agents, methods for preparing contrast agents, and methods of imaging. US9956304, 2018.
[85]
Kundra V, Bankson JA, Annapragada A, Ghaghada KB, Ravoori MK. Dual mode gadolinium nanoparticle contrast agents. US20150283272, 2015.
[86]
Gibson D. Pt(IV) prodrugs. WO2017115372, 2017.
[87]
Nakamura M, Fukuda T, Yamakawa K. Novel platinum (IV) complex. EP3315487, 2020.
[88]
Dhar S, Pathak R, Marrache S. Mitochondria-targeting platinum(IV) prodrug. WO2015157409, 2015.
[89]
Lippard SJ, Song Y, Suntharalingam K. Dual targeting anticancer agents. WO2014160216, 2015.
[90]
McFarland SA. Metal-based coordination complexes as photodynamic compounds and their use. US10766915, 2020.
[91]
Mandel A. Metal-glycoprotein complexes and their use as chemotherapeutic compounds.. US9737565, 2017.
[92]
Cai Z, Cang H, Sun B, Sun Y, Zhang H. Chitosan-platinum(IV) prodrug conjugate and preparation method thereof. CN104587486, 2015.
[93]
Wong KL, Wong WK. Multi-modal bioprobe for bladder cancer imaging and photodynamic therapy. US9840522, 2017.
[94]
Lin W, Liu D, Della Rocca J, Kramer SA, Poon CY. Metal bisphosphonate nanoparticles for anti-cancer therapy and imaging and for treating bone disorders. US9693957, 2017.
[95]
Messersmith PB, Black KCL IV, Yi J, Rivera JG. Multifunctional metal nanoparticles having a polydopamine-based surface and methods of making and using the same. US8784895, 2014.
[96]
Koob TJ. Cross-linked collagen comprising metallic anticancer agents. US8946163, 2015.
[97]
Jun YJ, Sohn YS. Tumor cell-selective and long-circulating micellar platinum anticancer agent and preparation method thereof. KR20110102995, 2011.
[98]
Hu X, Huang Y, Jing X, et al. Biodegradable high-polymer bonded photoactive Pt(IV) anticancer medicament micelle and preparation method thereof. CN102416181, 2013.
[99]
Lin IJB, Hsu THT, Chou S-H. Nanoparticles containing azolium and N-heterocyclic carbene compounds and use thereof. US9855280, 2018.
[100]
Farokhzad OC, Gadde SS, Karnik R, et al. Nanoparticles for targeted delivery of multiple therapeutic agents and methods of use. WO2014059022, 2014.
[101]
Abidi W, Cao P, Berlin J, Aboody K, Mooney R. Silica nanoparticle with platinum anti-cancer agent. WO2017117275, 2017.
[102]
Lin W, He C, Lu K. Nanoparticles for photodynamic therapy, X-ray induced photodynamic therapy, radiotherapy, chemotherapy, immunotherapy, and any combination thereof. US10780045, 2020.
[103]
Che CM, Chung YSC. Gold porphyrin-PEG conjugates and methods of use. US20170157261, 2017.
[104]
Lin S-Y. Caged platinum nanoclusters for anticancer chemotherapeutics. US9095616, 2015.
[105]
Fukunaga H, Dozono H, Hino A, Oshikiri S, Nagano A. Novel nitrogen-containing compound or salt thereof, or metal complex thereof. EP3050878A4, 2017.
[106]
Alberto R, Kunze SB, Castro HK, Mundwiler S. Metal complexes having vitamin B12 as a ligand. US7692002, 2010.
[107]
Contel M, Curado N, Lewis J, Poty S. Antibody-drug conjugates based on gold compounds. US20200016276, 2020.
[108]
Yano S, Shibahara T, Ogura S. Amino sugar-linked anticancer noble metal complex. JP6099052, 2017.
[109]
Chen H, Liu P, Gao Q, Lu Y. Glucose-containing platinum complex for treating tumors and preparation method thereof. CN102286050, 2011.
[110]
Chen H, Gao Q, Liu P, Lu Y. Galactose-containing platinum complex for tumour targeted therapy and preparation method thereof. CN102276674, 2011.
[111]
Liu Y, Wang Y. Application of sugar-containing platinum complex in preparation of medicines for preventing and treating tumor. CN102716145, 2012.
[112]
Wang P, Wang Q, Wang X. Glycosylation tetravalence platinum- like compounds with active anticancer, preparation method and application. CN105622673, 2018.
[113]
Chang Q, Hou S, Jiang J, Liu W, Lou L, Ye Q. Liver target platinum-containing anticancer drug and synthetic method thereof. CN104610415, 2016.
[114]
Krause ME, Laurence G, Mu QX, Stowell LJA. Therapeutic metal complexes. WO2015081117, 2015.
[115]
Xiao YD, Paudel R, Liu J, Ma C, Zhang ZS, Zhou SK. MRI contrast agents: Classification and application (Review). Int J Mol Med 2016; 38(5): 1319-26.
[http://dx.doi.org/10.3892/ijmm.2016.2744] [PMID: 27666161]
[116]
Akakuru OU, Iqbal MZ, Saeed M, et al. The transition from metal-based to metal-free contrast agents for T1 magnetic resonance imaging enhancement. Bioconjug Chem 2019; 30(9): 2264-86.
[http://dx.doi.org/10.1021/acs.bioconjchem.9b00499] [PMID: 31380621]
[117]
Kenny RG, Chuah SW, Crawford A, Marmion CJ. Platinum(IV) prodrugs - a step closer to Ehrlich’s vision? Eur J Inorg Chem 2017; 12: 1596-612.
[http://dx.doi.org/10.1002/ejic.201601278]
[118]
Wang Z, Deng Z, Zhu G. Emerging platinum(iv) prodrugs to combat cisplatin resistance: From isolated cancer cells to tumor microenvironment. Dalton Trans 2019; 48(8): 2536-44.
[http://dx.doi.org/10.1039/C8DT03923B] [PMID: 30633263]
[119]
Basu U, Banik B, Wen R, Pathak RK, Dhar S. The platin-X series: Activation, targeting, and delivery. Dalton Trans 2016; 45(33): 12992-3004.
[http://dx.doi.org/10.1039/C6DT01738J] [PMID: 27493131]
[120]
Eckschlager T, Plch J, Stiborova M, Hrabeta J. Histone deacetylase inhibitors as anticancer drugs. Int J Mol Sci 2017; 18(7): 1414.
[http://dx.doi.org/10.3390/ijms18071414] [PMID: 28671573]
[121]
Weinberg SE, Chandel NS. Targeting mitochondria metabolism for cancer therapy. Nat Chem Biol 2015; 11(1): 9-15.
[http://dx.doi.org/10.1038/nchembio.1712] [PMID: 25517383]
[122]
Darwish MA, Abo-Youssef AM, Khalaf MM, Abo-Saif AA, Saleh IG, Abdelghany TM. Vitamin E mitigates cisplatin-induced nephrotoxicity due to reversal of oxidative/nitrosative stress, suppression of inflammation and reduction of total renal platinum accumulation. J Biochem Mol Toxicol 2017; 31(1): 1-9.
[http://dx.doi.org/10.1002/jbt.21833] [PMID: 27550472]
[123]
Ferreira dos Santos A, Queiroz de Almeida DR, Ferreira Terra L, Baptista MS, Labriola L. Photodynamic therapy in cancer treatment - an update review. J Cancer Metastasis Treat 2019; 5: 25.
[124]
Zhao X, Liu J, Fan J, Chao H, Peng X. Recent progress in photosensitizers for overcoming the challenges of photodynamic therapy: From molecular design to application. Chem Soc Rev 2021; 50(6): 4185-219.
[http://dx.doi.org/10.1039/D0CS00173B] [PMID: 33527104]
[125]
Bonnet S. Why develop photoactivated chemotherapy? Dalton Trans 2018; 47(31): 10330-43.
[http://dx.doi.org/10.1039/C8DT01585F] [PMID: 29978870]
[126]
Imberti C, Zhang P, Huang H, Sadler PJ. New designs for phototherapeutic transition metal complexes. Angew Chem Int Ed Engl 2020; 59(1): 61-73.
[http://dx.doi.org/10.1002/anie.201905171] [PMID: 31310436]
[127]
Tiwari G, Tiwari R, Sriwastawa B, et al. Drug delivery systems: An updated review. Int J Pharm Investig 2012; 2(1): 2-11.
[http://dx.doi.org/10.4103/2230-973X.96920] [PMID: 23071954]
[128]
Liu XY, Wang JQ, Ashby CR Jr, Zeng L, Fan YF, Chen ZS. Gold nanoparticles: Synthesis, physiochemical properties and therapeutic applications in cancer. Drug Discov Today 2021; 26(5): 1284-92.
[http://dx.doi.org/10.1016/j.drudis.2021.01.030] [PMID: 33549529]
[129]
Caldorera-Moore M, Guimard N, Shi L, Roy K. Designer nanoparticles: Incorporating size, shape and triggered release into nanoscale drug carriers. Expert Opin Drug Deliv 2010; 7(4): 479-95.
[http://dx.doi.org/10.1517/17425240903579971] [PMID: 20331355]
[130]
Muhamad N, Plengsuriyakarn T, Na-Bangchang K. Application of active targeting nanoparticle delivery system for chemotherapeutic drugs and traditional/herbal medicines in cancer therapy: A systematic review. Int J Nanomedicine 2018; 13: 3921-35.
[http://dx.doi.org/10.2147/IJN.S165210] [PMID: 30013345]
[131]
Su S, Kang PM. Systemic review of biodegradable nanomaterials in nanomedicine. Nanomaterials (Basel) 2020; 10(4): 656.
[http://dx.doi.org/10.3390/nano10040656] [PMID: 32244653]
[132]
Zhang Y, Huang Y, Li S. Polymeric micelles: nanocarriers for cancer-targeted drug delivery. AAPS PharmSciTech 2014; 15(4): 862-71.
[http://dx.doi.org/10.1208/s12249-014-0113-z] [PMID: 24700296]
[133]
Greish K. Enhanced Permeability and Retention (EPR) effect for anticancer nanomedicine drug targeting. Methods Mol Biol 2010; 624: 25-37.
[http://dx.doi.org/10.1007/978-1-60761-609-2_3] [PMID: 20217587]
[134]
Lu Y, Zhang E, Yang J, Cao Z. Strategies to improve micelle stability for drug delivery. Nano Res 2018; 11(10): 4985-98.
[http://dx.doi.org/10.1007/s12274-018-2152-3] [PMID: 30370014]
[135]
Zhang Y, Sun T, Jiang C. Biomacromolecules as carriers in drug delivery and tissue engineering. Acta Pharm Sin B 2018; 8(1): 34-50.
[http://dx.doi.org/10.1016/j.apsb.2017.11.005] [PMID: 29872621]
[136]
Zhao Y. Surface-cross-linked micelles as multifunctionalized organic nanoparticles for controlled release, light harvesting, and catalysis. Langmuir 2016; 32(23): 5703-13.
[http://dx.doi.org/10.1021/acs.langmuir.6b01162] [PMID: 27181610]
[137]
Yi Y, Lin G, Chen S, Liu J, Zhang H, Mi P. Polyester micelles for drug delivery and cancer theranostics: Current achievements, progresses and future perspectives. Mater Sci Eng C 2018; 83: 218-32.
[http://dx.doi.org/10.1016/j.msec.2017.10.004] [PMID: 29208282]
[138]
Majumder N, G Das N, Das SK. Polymeric micelles for anticancer drug delivery. Ther Deliv 2020; 11(10): 613-35.
[http://dx.doi.org/10.4155/tde-2020-0008] [PMID: 32933425]
[139]
Petanidis S, Kioseoglou E, Salifoglou A. Metallodrugs in targeted cancer therapeutics: Aiming at chemoresistance- related patterns and immunosuppressive tumor networks. Curr Med Chem 2019; 26(4): 607-23.
[http://dx.doi.org/10.2174/0929867324666171116125908] [PMID: 29149832]
[140]
Ojima I. Guided molecular missiles for tumor-targeting chemotherapy-case studies using the second-generation taxoids as warheads. Acc Chem Res 2008; 41(1): 108-19.
[http://dx.doi.org/10.1021/ar700093f] [PMID: 17663526]
[141]
Baudino TA. Targeted cancer therapy: The next generation of cancer treatment. Curr Drug Discov Technol 2015; 12(1): 3-20.
[http://dx.doi.org/10.2174/1570163812666150602144310] [PMID: 26033233]
[142]
Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell 2011; 144(5): 646-74.
[http://dx.doi.org/10.1016/j.cell.2011.02.013] [PMID: 21376230]
[143]
Alday-Parejo B, Stupp R, Rüegg C. Are integrins still practicable targets for anti-cancer therapy? Cancers (Basel) 2019; 11(7): 978.
[http://dx.doi.org/10.3390/cancers11070978] [PMID: 31336983]
[144]
Danhier F, Le Breton A, Préat V. RGD-based strategies to target alpha(v) beta(3) integrin in cancer therapy and diagnosis. Mol Pharm 2012; 9(11): 2961-73.
[http://dx.doi.org/10.1021/mp3002733] [PMID: 22967287]
[145]
Nielsen MJ, Rasmussen MR, Andersen CB, Nexø E, Moestrup SK. Vitamin B12 transport from food to the body’s cells-a sophisticated, multistep pathway. Nat Rev Gastroenterol Hepatol 2012; 9(6): 345-54.
[http://dx.doi.org/10.1038/nrgastro.2012.76] [PMID: 22547309]
[146]
Waibel R, Treichler H, Schaefer NG, et al. New derivatives of vitamin B12 show preferential targeting of tumors. Cancer Res 2008; 68(8): 2904-11.
[http://dx.doi.org/10.1158/0008-5472.CAN-07-6771] [PMID: 18413759]
[147]
Pettenuzzo A, Pigot R, Ronconi L. Vitamin B12-metal conjugates for targeted chemotherapy and diagnosis: Current status and future prospects. Eur J Inorg Chem 2017; 12: 1625-38.
[http://dx.doi.org/10.1002/ejic.201601217]
[148]
Singh S, Kumar NK, Dwiwedi P, et al. Monoclonal antibodies: A review. Curr Clin Pharmacol 2018; 13(2): 85-99.
[http://dx.doi.org/10.2174/1574884712666170809124728] [PMID: 28799485]
[149]
Zahavi D, Weiner L. Monoclonal antibodies in cancer therapy. Antibodies (Basel) 2020; 9(3): 34.
[http://dx.doi.org/10.3390/antib9030034] [PMID: 32698317]
[150]
Del Solar V, Contel M. Metal-based antibody drug conjugates. Potential and challenges in their application as targeted therapies in cancer. J Inorg Biochem 2019; 199: 110780.
[http://dx.doi.org/10.1016/j.jinorgbio.2019.110780] [PMID: 31434020]
[151]
Harris RA. Glycolytic pathway. In: Maccarrone M, Ed. Encyclopedia of life sciences. Chichester: John Wiley & Sons 2015.
[http://dx.doi.org/10.1002/9780470015902.a0000619.pub3]
[152]
Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: The metabolic requirements of cell proliferation. Science 2009; 324(5930): 1029-33.
[http://dx.doi.org/10.1126/science.1160809] [PMID: 19460998]
[153]
Macheda ML, Rogers S, Best JD. Molecular and cellular regulation of Glucose Transporter (GLUT) proteins in cancer. J Cell Physiol 2005; 202(3): 654-62.
[http://dx.doi.org/10.1002/jcp.20166] [PMID: 15389572]
[154]
Krzeslak A, Wojcik-Krowiranda K, Forma E, et al. Expression of GLUT1 and GLUT3 glucose transporters in endometrial and breast cancers. Pathol Oncol Res 2012; 18(3): 721-8.
[http://dx.doi.org/10.1007/s12253-012-9500-5] [PMID: 22270867]
[155]
Jang M, Kim SS, Lee J. Cancer cell metabolism: Implications for therapeutic targets. Exp Mol Med 2013; 45(10): e45.
[http://dx.doi.org/10.1038/emm.2013.85] [PMID: 24091747]
[156]
Zhao Y, Butler EB, Tan M. Targeting cellular metabolism to improve cancer therapeutics. Cell Death Dis 2013; 4(3): e532.
[http://dx.doi.org/10.1038/cddis.2013.60] [PMID: 23470539]
[157]
Pettenuzzo A, Pigot R, Ronconi L. Metal-based glycoconjugates and their potential in targeted anticancer chemotherapy. Metallodrugs 2015; 1(1): 36-61.
[158]
Rubio-Aliaga I, Daniel H. Peptide transporters and their roles in physiological processes and drug disposition. Xenobiotica 2008; 38(7-8): 1022-42.
[http://dx.doi.org/10.1080/00498250701875254] [PMID: 18668438]
[159]
Tai W, Chen Z, Cheng K. Expression profile and functional activity of peptide transporters in prostate cancer cells. Mol Pharm 2013; 10(2): 477-87.
[http://dx.doi.org/10.1021/mp300364k] [PMID: 22950754]
[160]
Brandsch M, Knütter I, Bosse-Doenecke E. Pharmaceutical and pharmacological importance of peptide transporters. J Pharm Pharmacol 2008; 60(5): 543-85.
[http://dx.doi.org/10.1211/jpp.60.5.0002] [PMID: 18416933]
[161]
Brandsch M. Transport of drugs by proton-coupled peptide transporters: pearls and pitfalls. Expert Opin Drug Metab Toxicol 2009; 5(8): 887-905.
[http://dx.doi.org/10.1517/17425250903042292] [PMID: 19519280]
[162]
Celegato M, Fregona D, Mongiat M, et al. Preclinical activity of multiple-target gold(III)-dithiocarbamato peptidomimetics in prostate cancer cells and xenografts. Future Med Chem 2014; 6(11): 1249-63.
[http://dx.doi.org/10.4155/fmc.14.81] [PMID: 25162999]
[163]
Wouters OJ, McKee M, Luyten J. Estimated research and development investment needed to bring a new medicine to market, 2009-2018. JAMA 2020; 323(9): 844-53.
[http://dx.doi.org/10.1001/jama.2020.1166] [PMID: 32125404]

Rights & Permissions Print Cite
Article Metrics
30
1
© 2024 Bentham Science Publishers | Privacy Policy